Home > Healthcare > Pharmaceuticals > Finished Drug Form > U.S. Peptide Therapeutics Market

U.S. Peptide Therapeutics Market Size

Report ID: GMI7400
Published Date: Nov 2023
Report Format: PDF

Download Free Sample

U.S. Peptide Therapeutics Market Size

U.S Peptide Therapeutics Market was valued to be around USD 17.8 billion in 2022 and is projected to witness massive growth at a CAGR of around 7% from 2023 to 2032. The factors driving the market growth are increasing prevalence of chronic disorders, rising healthcare expenditure, technological advancements, and growing disposable income in the country.

To get key market trends

Download Free Sample

Moreover, rising incidences of metabolic disorders, cancer, cardiovascular disorders, gastrointestinal disorders, and central nervous system disorders are increasing the demand for effective peptide therapeutics for such conditions.

Peptides consist of short chains of amino acids connected by peptide bonds. Peptide therapeutics serve as crucial replacement therapies that supplement peptide hormones when there are insufficient endogenous levels. Peptides bind to specific surface receptors and their ligands on cells, thus aiding in the treatment of diseases by influencing the cell membrane.

U.S. Peptide Therapeutics Market Report Attributes
Report Attribute	Details
Base Year:	2022
U.S. Peptide Therapeutics Market Size in 2022:	USD 17.8 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	7%
2032 Value Projection:	USD 35.7 Billion
Historical Data for:	2018 to 2022
No. of Pages:	140
Tables, Charts & Figures:	82
Segments covered:	Type, Application, Route of administration, Manufacturer type, Synthesis technology, Distribution channel
Growth Drivers:	Increasing prevalence of cancer in the U.S. Rising incidences of metabolic disorders Increasingzinvestments in R&D of novel drugs Technological advancement in peptide therapeutics
Pitfalls & Challenges:	Stringent regulatory requirements for drug approval High cost for drug development

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

U.S peptide therapeutics industry size was USD 17.8 billion in 2022 and is expected to register 7% CAGR from 2023-2032 due to the increasing prevalence of chronic disorders, rising healthcare expenditure, technological advancements, and the growing disposable incomes in the region.

U.S peptide therapeutics industry from the branded type segment is expected to record USD 22,830 million by 2032 owing to the higher number of prescriptions for branded drugs, and the perceived quality and efficacy of branded peptide therapeutics compared to generics.

U.S peptide therapeutics industry size from the in-house manufacturer segment held 64.4% share in 2022 owing to the increasing focusing on developing peptide therapeutics in-house due to the high costs and stringent outsourcing regulatory requirements.

Pfizer, Inc., Amgen, Inc., Eli Lilly and Company, Sanofi, AstraZeneca plc, AbbVie, and GlaxoSmithKline plc are some of the major peptide therapeutics companies in the U.S.